Aptevo Therapeutics (APVO)

• Aptevo Therapeutics secured a $60 million standby equity purchase and equity line of credit with Yorkville Advisors, which, combined with existing cash, is expected to extend its funding runway into 2029.
• This facility provides incremental, discretionary access to capital over 36 months, subject to Nasdaq share caps and a 9.99% ownership limit for Yorkville.
• Despite this financing and encouraging clinical progress with lead candidate mipletamig, analysts continue to flag significant financial risks, including no revenue, heavy cash burn, and weak fundamentals.
• GuruFocus noted Aptevo's very small market capitalization (approximately $8.61 million) and a weak Piotroski F-Score, alongside strong liquidity ratios.

• Aptevo Therapeutics Inc. entered into a $60 million equity line of credit (ELOC) agreement with Yorkville Advisors Global, LP on January 8, 2026.
• This financing, combined with cash on hand, is expected to extend Aptevo's funding runway into 2029, supporting ongoing clinical development, preclinical programs, and general corporate purposes.
• Under the terms, Aptevo has the right, but not the obligation, to sell shares to Yorkville at a price equal to 96% of the lowest daily volume-weighted average price (VWAP) during a three-day period.
• The company incurred a $25,000 structuring fee and a 2.00% commitment fee on the $60 million commitment amount, payable in five equal quarterly installments.

• Aptevo Therapeutics Inc. (APVO) announced a 1-for-18 reverse stock split of its common stock, effective at 5:01 p.m. Eastern Time on December 29, 2025.
• The company's stockholders approved a series of alternate amendments for a reverse stock split at a Special Meeting on July 24, 2025, with the Board of Directors subsequently approving the 1-for-18 ratio on December 17, 2025.
• As a result of the split, every 18 shares of issued and outstanding common stock were automatically combined into one share, with proportionate adjustments to outstanding stock options, restricted stock units, and warrants.
• The common stock will begin trading on The Nasdaq Capital Market on a split-adjusted basis when the market opens on December 30, 2025.

• Aptevo Therapeutics announced a 1-for-18 reverse stock split effective December 29, 2025, primarily to maintain Nasdaq listing compliance.
• The company's stock tumbled sharply, falling 36-45% to all-time lows near $0.52-$0.60, reflecting significant selling pressure ahead of the split.
• As a clinical-stage biotech, Aptevo currently has no revenue, a market capitalization under $10 million, and reported a wider Q3 net loss of $7.5 million.
• Aptevo raised $18.7 million in Q3 and an additional $4.1 million after quarter-end, extending its cash runway into late 2026 to advance its immunotherapeutic candidates.

• Aptevo Therapeutics Inc. announced compelling safety and strong remission rates for its drug candidate, mipletamig, in frontline acute myeloid leukemia (AML) from its Phase 1b/2 RAINIER trial.
• The data, presented at ASH 2025, showed that 100% of treated patients remained free of cytokine release syndrome (CRS) across dose-optimization Cohorts 1-3.
• Key efficacy findings include a 93% overall response rate (ORR) among evaluable patients, with 87% achieving CR/CRi and 73% achieving complete remission (CR).
• The triplet regimen of mipletamig combined with AZA/VEN was generally well tolerated in newly diagnosed AML patients unfit for intensive chemotherapy.

Aptevo Therapeutics Inc. reported its financial results for the third quarter ended September 30, 2025.

• The company raised $18.7 million, net in Q3 2025 and an additional $4.1 million, net since quarter end, extending its cash runway well into 4Q26.
• In clinical trials, 89% of evaluable frontline AML patients achieved remission with mipletamig in combination therapy, including 100% remission in Cohort 3 of the RAINIER trial, with no cytokine release syndrome observed.
• Aptevo introduced its first trispecific T-cell engagers, APVO451 and APVO452, expanding its oncology portfolio to five CRIS-7-derived CD3-targeting molecules designed to overcome immune suppression in solid tumors.

• OmniAb reported revenue of $2.2 million for the third quarter of 2025, a decrease from $4.2 million in the same period of 2024, and a net loss of $16.5 million, or $0.14 per share.
• For the nine months ended September 30, 2025, OmniAb's revenue was $10.3 million and the net loss was $50.6 million, or $0.46 per share.
• The company updated its 2025 financial guidance, now expecting revenue in the range of $18 million to $22 million and operating expenses between $82 million and $86 million.
• As of September 30, 2025, OmniAb had $59.5 million in cash, cash equivalents, and short-term investments, following a $30 million private placement in August.
• OmniAb expanded its partnerships to 104 active partners and 399 active programs as of September 30, 2025, and plans to launch its new OmniUltra™ technology in December 2025.

• Aptevo Therapeutics Inc. reported a 100% remission rate in Cohort 3 of its Phase 1b/2 RAINIER trial evaluating mipletamig for newly diagnosed acute myeloid leukemia (AML) patients unfit for intensive chemotherapy.
• The trial has observed no dose-limiting toxicities or cytokine release syndrome to date, demonstrating a consistently favorable safety and tolerability profile for mipletamig.
• Additionally, 40% of patients treated in the RAINIER trial have achieved minimal residual disease (MRD)-negative status, which is a critical marker associated with improved overall outcomes in AML.
• Cohort 3 enrollment is complete, and Cohort 4 is actively enrolling patients at the next dose level, with current findings anticipated to be presented at a major medical conference in Q4.